70. 広範脊柱管狭窄症
[臨床試験数:91,薬物数:195(DrugBank:54),標的遺伝子数:60,標的パスウェイ数:85]
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04308122 (ClinicalTrials.gov) | October 1, 2020 | 6/3/2020 | Cervical Orthosis Versus no Orthosis Following Multi-level Posterior Cervical Fusion | A Randomized Trial of Cervical Orthosis Versus no Orthosis Following Multi-level Posterior Cervical Fusion | Posterior Cervical Spinal Surgery;Myelopathy Cervical;Radiculopathy, Cervical;Spinal Stenosis Cervical;Spondylosis, Cervical | Device: Cervical Orthosis (CO);Device: No Orthosis | Dr. Christopher Bailey | NULL | Recruiting | 18 Years | N/A | All | 40 | N/A | Canada |
2 | NCT04483297 (ClinicalTrials.gov) | October 2020 | 14/7/2020 | First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) | First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft Fusion Surgery | Degenerative Spondylolisthesis;Spinal Stenosis | Drug: AK1320 MS;Other: Control | Asahi Kasei Pharma Corporation | Emergent Clinical Consulting | Recruiting | 22 Years | 80 Years | All | 40 | Phase 1 | Canada |
3 | NCT04066296 (ClinicalTrials.gov) | September 2020 | 3/7/2019 | Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine | A Double Blinded Randomized Control Trial in Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine | Lumbar Spinal Stenosis | Drug: Liposomal bupivacaine | University of Colorado, Denver | NULL | Not yet recruiting | 18 Years | N/A | All | 100 | Phase 2 | NULL |
4 | NCT04492774 (ClinicalTrials.gov) | July 1, 2020 | 20/7/2020 | Degenerative Lumbar Stenosis Conservative Treatment | GOLDIC Therapy in Lumbar Degenerative Spinal Stenosis - Randomized Controlled Trial | Spinal Stenosis Lumbar;Spinal Canal Stenosis | Combination Product: Goldic serum;Drug: Steroid injections;Procedure: Manual therapy | Sutherland Medical Center | NULL | Recruiting | 18 Years | N/A | All | 90 | Phase 4 | Poland |
5 | JPRN-jRCTs021200007 | 19/06/2020 | 03/06/2020 | MiroTAS | Efficacy and Safety of Mirogabalin for the Treatment as Add-On to NSAIDs in patients with Peripheral Neuropathic Pain caused by Lumbar Spinal Stenosis : Multi-institutional, randomized, open, parallel-design and interventional Study | Lumber Spiral Stenosis | Comparison in the effect and safety of Mirogabalin add-on therapy to NSAIDs and NSAIDs monotherapy for patients with Lumber Spiral Stenosis and administrated of NSAIDs. 1) NSAIDs monotherapy as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated. 2) Mirogabalin add-on therapy to NSAIDs: NSAIDS as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated. Mirogabalin is prescribed as follows in accordance with renal function of a subject. Patients with creatinine clearance more than 60mL/min: Mirogabalin is administrated in dose of 5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 10mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 15mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 10mg twice a day or 15mg twice a day depending on safety findings. Patients with creatinine clearance 30-60mL/min: Mirogabalin is administrated in dose of 2.5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 5mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 7.5mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 5mg twice a day or 7.5mg twice a day depending on safety findings. Also, more than 7 days washout period before enrollment is required for target patients administrated of prohibited drugs. If the administration of Mirogabalin is discontinued, down-titration is needed in accordance with the insert package. | Nikaido Takuya | Daiichi Sankyo Co., Ltd | Recruiting | >= 20age old | Not applicable | Both | 300 | N/A | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | EUCTR2019-003590-25-NL (EUCTR) | 15/06/2020 | 15/06/2020 | Epidural analgesia after back surgery | a Randomized controlled trial for epidural Analgesia for Pain relief after lumbar Interlaminar Decompressive spine surgery - RAPID - RAPID | Lumbar spinal stenosis MedDRA version: 21.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml Product Name: Bupivacaine Product Code: Sufentanil | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 34 | Phase 4 | Netherlands | |||
7 | NCT04401735 (ClinicalTrials.gov) | November 1, 2019 | 11/5/2020 | Effects and Safety of Epidural PDRN vs. Placebo | Effects and Safety of PDRN (Polydeoxyribonucleotide) for Patient With Lumbar Spinal Stenosis Compared With Normal Saline in Randomized Placebo-Controlled Comparative Pilot Study | Spinal Stenosis Lumbar | Drug: Polydeoxyribonucleotides;Drug: Normal saline | Seoul National University Hospital | NULL | Recruiting | 19 Years | 80 Years | All | 45 | Phase 4 | Korea, Republic of |
8 | NCT04611464 (ClinicalTrials.gov) | July 11, 2019 | 9/10/2020 | Misoprostol for Spinal Stenosis | Pain and Functional Outcomes With Misoprostol Treatment for Lumbar Spinal Stenosis | Lumbar Spinal Stenosis;Low Back Pain | Drug: Misoprostol | Dallas VA Medical Center | NULL | Completed | 18 Years | N/A | All | 23 | United States | |
9 | NCT04042948 (ClinicalTrials.gov) | June 24, 2019 | 13/7/2019 | Clinical Effect of Preventive Use of Tylenol on Fever After Removal of Drainage Tube in Lumbar Fusion Surgery | Randomized Controlled Study of Fever Probability, Risk Factors and Preventive Use of Non-steroidal Anti-inflammatory Drugs on Fever After Removal of Drainage Tube After Lumbar Fusion | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Radiculopathy | Drug: Tylenol | Peking University Third Hospital | NULL | Recruiting | 18 Years | N/A | All | 200 | N/A | China |
10 | NCT03745040 (ClinicalTrials.gov) | January 26, 2019 | 5/11/2018 | Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion | Does Liposomal Bupivacaine Improve Postoperative Pain Control After One Level Posterior Spinal Fusion With Instrumentation | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Disc Disease;Lumbar Spondylolisthesis | Drug: Liposomal bupivacaine | Allina Health System | Twin Cities Spine Center | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT04559295 (ClinicalTrials.gov) | November 21, 2018 | 31/8/2020 | Bone Marrow Concentrate (BMC) Injection in Intervertebral Discs | Study of Bone of Marrow Concentrate (BMC) Injection in Discs, Facets, Sacroiliac Joints, and Epidural Space for Chronic Lower Back Pain With and Without Radiculopathy | Low Back Pain;Disc Disease;Disc Degeneration;Arthropathy Vertebrae;Sacral Disorder;Radiculopathy;Spinal Stenosis | Biological: Bone Marrow Concentrate | Stem Cures | NULL | Active, not recruiting | 18 Years | 60 Years | All | 80 | Phase 2;Phase 3 | United States |
12 | NCT03883022 (ClinicalTrials.gov) | September 3, 2018 | 10/3/2019 | Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery | Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery | Spinal Fusion;Spinal Stenosis;Spondylolisthesis | Drug: with U-VANCO (vancomycin hydrochloride);Drug: without U-VANCO (vancomycin hydrochloride) | Taipei Veterans General Hospital, Taiwan | NULL | Recruiting | 20 Years | N/A | All | 400 | N/A | Taiwan |
13 | NCT03647501 (ClinicalTrials.gov) | August 22, 2018 | 21/8/2018 | Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages | Lumbar Fusion With 3D-Printed Porous Titanium Interbody Cages - A Single-Blinded Randomized Controlled Trial Evaluating Nexxt Matrixx(TM) Versus PEEK Cages | Lumbar Degenerative Disc Disease;Lumbar Spinal Stenosis;Lumbar Spondylolisthesis;Lumbar Spinal Deformity;Lumbar Spondylosis | Device: Interbody cage (titanium);Device: Interbody cage (PEEK) | Ohio State University | Nexxt Spine, LLC | Recruiting | 18 Years | N/A | All | 70 | N/A | United States |
14 | NCT03047044 (ClinicalTrials.gov) | July 1, 2018 | 5/2/2017 | The Comparison of Postoperative Pain After Lumbar Fusion Surgery in Intravenous Patient-controlled Analgesia Between Conventional Mode and Optimizing B.I Mode With 'PAINSTOP' Equipment | The Comparison of Postoperative Pain After Lumbar Fusion Surgery in Intravenous Patient-controlled Analgesia Between Conventional Mode and Optimizing B.I Mode With 'PAINSTOP' Equipment | Back Pain;Fusion of Spine, Lumbar Region;Spinal Stenosis | Other: Optimizing basal infusion (B.I);Other: Conventional PCA mode | Yonsei University | NULL | Completed | 20 Years | 70 Years | All | 58 | N/A | Korea, Republic of |
15 | NCT03584074 (ClinicalTrials.gov) | July 1, 2018 | 29/6/2018 | Clinical Trial of Pregabalin and COX2 in Spinal Stenosis | Comparative Study for Decrease of Pain Intensity and Pain Sensitivity Between Pregabalin + COX-2 Inhibitor and COX-2 Inhibitor in Patients With Lumbar Spinal Stenosis: Randomized Controlled Trial | Spinal Stenosis Lumbar | Drug: Pregabalin 75mg;Drug: Celebrex 200Mg Capsule | Seoul National University Bundang Hospital | NULL | Unknown status | 40 Years | N/A | All | 60 | Phase 4 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | JPRN-JapicCTI-183866 | 02/2/2018 | 15/02/2018 | Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study) | Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study) | LSS | Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration Control intervention name : NS-304 Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral administration | Nippon Shinyaku Co., Ltd. | NULL | complete | 40 | 79 | BOTH | 120 | Phase 2 | Japan |
17 | JPRN-UMIN000030881 | 2018/01/18 | 18/01/2018 | Dietary supplementation in patients following lumbar spine surgery: a randomized controlled trial | Dietary supplementation in patients following lumbar spine surgery: a randomized controlled trial - Dietary supplementation in patients following lumbar spine surgery | lumbar spinal stenosis | Intervention group Twice-daily ingestion of amino acids supplementation for 3 weeks after spinal surgery (100kcal, protein 10g) Postoperative rehabilitation for 3 weeks Control group Twice-daily ingestion of placebo (non amino acids) supplementation for 3 weeks after spinal surgery (100kcal, protein 0g ) Postoperative rehabilitation for 3 weeks | Wakayama Medical University | NULL | Recruiting | 50years-old | 90years-old | Male and Female | 80 | Not selected | Japan |
18 | NCT03088306 (ClinicalTrials.gov) | July 1, 2017 | 22/2/2017 | Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients | Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery | Lumbar Spinal Stenosis;Lumbar Spinal Instability;Lumbar Spine Degeneration | Drug: Standard analgesia use [Oxygen];Drug: Standard analgesia use [Hydromorphone];Drug: Standard analgesia use [Volatile Anesthesia];Drug: Standard analgesia use [Fentanyl];Drug: Multi-modal pain management [Acetaminophen + Gabapentin];Drug: Multi-modal pain management [Fentanyl];Drug: Multi-modal pain management [Intravenous Ketamine];Drug: Multi-modal pain management [Valium + Gabapentin] | Johns Hopkins University | North American Spine Society | Completed | 18 Years | 100 Years | All | 49 | Early Phase 1 | United States |
19 | NCT03011866 (ClinicalTrials.gov) | February 2017 | 16/12/2016 | Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries | Intravenous Versus Topical Use of Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS) : A Prospective, Randomized, Double Blind, Head-to-head Comparison Study | Spinal Stenosis;Intervertebral Disc Displacement | Drug: Wound topically irrigated with 500mg TXA;Drug: 1mg/kg/hr TXA intravenous infusion till the last suture | Peking Union Medical College Hospital | NULL | Not yet recruiting | 50 Years | N/A | All | 176 | N/A | NULL |
20 | EUCTR2016-002887-14-FI (EUCTR) | 31/10/2016 | 14/10/2016 | Dose-response of ketamine in patient controlled analgesia in orthopaedic surgery patients | Dose response study of Patient Controlled Analgesia (PCA) of S-ketamine in orthopaedic spine surgery patients - DoseRespKeta | Patients who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation MedDRA version: 19.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] | Trade Name: Ketanest-S INN or Proposed INN: KETAMINE Trade Name: Oxycodone Orion INN or Proposed INN: OXYCODONE | University of Turku | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 1;Phase 4 | Finland | ||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
21 | NCT02939482 (ClinicalTrials.gov) | October 1, 2016 | 15/10/2016 | A Study Comparison of Clinical Outcome After Different Rate of Infusion in Caudal Epidural Steroid Injection | A Prospective Study Comparison of Clinical Outcome After Different Rate Infusion in Caudal Epidural Steroid Injection | Spinal Stenosis;Lumbosacral Spondylosis;Radiculopathy | Drug: Triamcinolone Acetonide and normal saline solution | Navamindradhiraj University | NULL | Completed | 20 Years | N/A | All | 112 | N/A | Thailand |
22 | NCT02902380 (ClinicalTrials.gov) | September 27, 2016 | 6/9/2016 | The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery | Spinal Stenosis | Drug: dexmedetomidine group;Drug: control group | Yonsei University | NULL | Completed | 20 Years | 70 Years | All | 52 | N/A | Korea, Republic of | |
23 | EUCTR2015-002694-37-FI (EUCTR) | 01/09/2016 | 04/01/2016 | Dexmedetomidine is a drug that is used mainly for sedation in the intensive care unit. Purpose of this study is to determine does Dexmedetomidine infusion provide pain management in the postoperative period and prevent chronic pain. Patients are randomized to receive either placebo or dexmedetomidine infusion. DEXPAIN-study has been approved by Kuopio university hospitals ethics committee. | Dexmedetomidine infusion in pain management during low back surgeryDexmedetomidine is an alpha-2-adrenergic agonist that is used mainly for sedation in the intensive care unit. Alpha-2-adrenoceptors agonists have several beneficial actions in a surgical patient. They decrease symphatetic tone, reduce anesthetic and opioid requirements and cause sedation and analgesia. Pain after low back surgery is intense and can become chronic. We need a new drug to manage pain during postoperative period and to prevent chronic pain.DEXPAIN-study has been approved by Kuopio university hospitals ethics committee. Study is single centered, randomized and placebo-controlled study. A total of 60 patients scheduled for low back surgery will be enrolled in this study. Patients eligibility will be assessed by pre-determined inclusion-exclusion-criteria. Purpose of this study is to determine does Dexmedetomidine infusion provide pain management in the postoperative period and prevent chronic pain. Patients are randomized to receive either placebo or dexmedetomidine infusion. Patients in the dexmedetomidine group receive dexmedetomidine loading dose 1ug/kg for 10 minutes and continuous infusion 1.4 ug/kg/h during surgery and post-anesthesia care unit. Total infusion time will be four hours. Anesthesia is standardized and post-operative pain is treated with patient controlled analgesia made of oxycodone. Questionnaires will be used to assess pain control.Study is scheduled to start as soon as we obtain permission from Finnish Medicines Agency and receive sufficient funding. | Low back pain, Discus prolapse, Spinal stenosis;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Trade Name: Dexmedetomidine Product Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE | Kuopio University hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | Finland | ||||
24 | NCT02838615 (ClinicalTrials.gov) | July 2016 | 25/5/2016 | Comparison of Transforaminal vs. Parasagittal Interlaminar Epidural Injection | Comparison of Lumbar Epidural Steroid Injection: Transforaminal vs. Parasagittal Interlaminar Approach | Spinal Stenosis | Procedure: epidural steroid (dexamethasone) injection | Keimyung University Dongsan Medical Center | NULL | Completed | N/A | N/A | All | 56 | N/A | NULL |
25 | NCT02826889 (ClinicalTrials.gov) | May 24, 2016 | 6/7/2016 | Assessing the Diagnostic Accuracy of Corrected Flow Time (FTc) and Pleth Variability Index (PVI) as Predictors of Fluid Responsiveness in Patients in the Prone Position Using the Jackson Table | Elective Posterior Lumbar Spinal Fusion for Spinal Stenosis;Spondylolisthesis;Spinal Fractures;Scoliosis or Tumors | Device: Philips Intelivue MP70 monitor;Device: Pleth Variability Index (PVI) | Yonsei University | NULL | Completed | 19 Years | 75 Years | All | 58 | N/A | Korea, Republic of | |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
26 | NCT02700451 (ClinicalTrials.gov) | March 2016 | 18/2/2016 | Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes | A Randomized Controlled Trial of Post-operative Acetaminophen Versus Nonsteroidal Anti-Inflammatory Drug (NSAID) Use on Lumbar Spinal Fusion Outcomes | Lumbar Osteoarthritis;Spondylosis;Lumbar Disc Disease;Spinal Stenosis | Drug: Ketorolac;Drug: Acetaminophen;Drug: Placebo | Hospital for Special Surgery, New York | NULL | Active, not recruiting | 18 Years | 75 Years | All | 300 | N/A | United States |
27 | NCT02625194 (ClinicalTrials.gov) | January 1, 2016 | 25/11/2015 | The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation | The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation | Lumbar Spinal Stenosis | Drug: Oxygen | Yonsei University | NULL | Completed | 20 Years | 60 Years | All | 36 | N/A | Korea, Republic of |
28 | NCT02444351 (ClinicalTrials.gov) | June 26, 2015 | 28/4/2015 | Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis | Spinal Stenosis With Nocturnal Calf Cramps | Drug: botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle;Other: no intervention | Yonsei University | NULL | Completed | 20 Years | 80 Years | All | 50 | N/A | Korea, Republic of | |
29 | EUCTR2014-003252-31-FI (EUCTR) | 15/05/2015 | 22/04/2015 | Dose-response of dexmedetomidine in patient controlled analgesia in orthopaedic surgery patients | Dose response study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in orthopaedic spine surgery patients - DoserespDex_2.0 | Patients, who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation MedDRA version: 17.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] | Trade Name: Dexdor INN or Proposed INN: deksmedetomidiini Other descriptive name: DEXMEDETOMIDINE HYDROCHLORIDE Trade Name: Oxanest INN or Proposed INN: oksikodoni Other descriptive name: OXYCODONE HYDROCHLORIDE | University of Turku | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
30 | NCT02416804 (ClinicalTrials.gov) | January 2015 | 10/4/2015 | Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery | Postoperative Analgesia With Buprenorphine Transdermal System (BTDS) Versus Tramadol for Postoperative Pain Control and Quality of Life After Spinal Surgery | Spinal Stenosis;Pain, Postoperative | Drug: Buprenorphine;Drug: Tramadol | Seoul National University Hospital | NULL | Completed | 20 Years | N/A | All | 69 | Phase 4 | Korea, Republic of |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
31 | NCT02093520 (ClinicalTrials.gov) | May 2014 | 18/3/2014 | The MiDAS ENCORE Study | MILD® Percutaneous Image-Guided Lumbar Decompression Versus Epidural Steroid Injections in Patients With Lumbar Spinal Stenosis Exhibiting Neurogenic Claudication | Spinal Stenosis, Lumbar Region, With Neurogenic Claudication | Procedure: MILD Procedure;Drug: Epidural Steroid Injection | Vertos Medical, Inc. | NULL | Completed | 65 Years | N/A | All | 302 | N/A | United States |
32 | NCT02103543 (ClinicalTrials.gov) | January 2014 | 27/3/2014 | Comparison of the Order of Treatment in Lumbar Spinal Stenosis | A Randomized Trial in Patients With Lumbar Spinal Stenosis, Comparing the Order of Treatment With Epidural Corticosteroid Injections and Physical Therapy | Lumbar Spinal Stenosis | Other: physical therapy;Procedure: lumbar interlaminar epidural steroid injection;Drug: epidural steroid injection | Emory University | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | N/A | United States |
33 | NCT01934868 (ClinicalTrials.gov) | December 1, 2013 | 30/8/2013 | Prolotherapy Versus Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg | A Comparison of the Long Term Outcomes of Prolotherapy Versus Interlaminar Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg | Sciatica;Spinal Stenosis of Lumbar Region;Degeneration of Lumbar or Lumbosacral Intervertebral Disc | Drug: prolotherapy solution of 20% dextrose;Drug: Epidural Steroid Injection | Hadassah Medical Organization | Reuth Rehabilitation Hospital | Active, not recruiting | 18 Years | 90 Years | All | 110 | Phase 4 | Israel |
34 | NCT01943435 (ClinicalTrials.gov) | November 20, 2013 | 8/9/2013 | Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis) | A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis | Lumbar Spinal Stenosis | Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;Procedure: Lumbar epidural injection;Other: Joint Mobilizations (spine, sacroiliac, hip);Other: Individualized exercises: clinical setting;Other: Group Exercise: community setting | Michael Schneider, DC, PhD | Patient-Centered Outcomes Research Institute | Completed | 60 Years | N/A | All | 259 | N/A | United States |
35 | NCT01888536 (ClinicalTrials.gov) | February 2013 | 25/6/2013 | A Study to Evaluate Efficacy of ?Opast Tablet?for Neurologic Claudication in Patients With Lumbar Spinal Stenosis | A Randomized, Double-Blind, Comparative, Multi-Center, Phase ? Clinical Trial to Evaluate Efficacy of ?Opast Tablet?for Neurologic Claudication in Patients With Lumbar Spinal Stenosis | Neurologic Claudication in Patients With Lumbar Spinal Stenosis | Drug: Limaprost;Drug: Pregabalin;Drug: Placebo(for Pregabalin);Drug: Placebo(for Limaprost) | Yungjin Pharm. Co., Ltd. | NULL | Completed | 20 Years | 75 Years | Both | 182 | Phase 4 | Korea, Republic of |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
36 | ChiCTR-TRC-13003639 | 2012-09-13 | 2013-09-07 | The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery | The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery | Lumbar spinal stenosis and/or lumbar intervertebral disc herniation | ANI group:ANI guide the administration of remifentanil;control group:remifentanil was adapted by Anaesthesiologist corresponding to clinical experiences ; | Peking University Third Hospital | NULL | Completed | 18 | 70 | Both | ANI group:30;control group:30; | China | |
37 | NCT02063035 (ClinicalTrials.gov) | August 2012 | 19/12/2013 | Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery | Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery | Lumbar Spinal Stenosis;Thoracic Spinal Stenosis | Drug: Tranexamic Acid;Drug: Placebo | Massachusetts General Hospital | NULL | Completed | 18 Years | 85 Years | All | 29 | Phase 4 | United States |
38 | NCT02090244 (ClinicalTrials.gov) | August 2012 | 16/3/2014 | Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans? | Förbättrar PTH Postero-lateral fusionsläkning Vid Ryggkirurgi? | Spinal Stenosis | Drug: Teriparatide | University Hospital, Linkoeping | Medical Research Council of Southeast Sweden | Completed | N/A | N/A | All | 34 | Phase 4 | Sweden |
39 | EUCTR2011-006152-36-DK (EUCTR) | 10/05/2012 | 10/05/2012 | Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing? | Postoperative treatment with parathyroidea hormone Forteo® inpatients undergoing posterolateral spinal fusion surgery. A prospektiveand a randomized double-blinded, placebo-controlled study - PTH-U-DESE-STUDY | Spinal stenosis MedDRA version: 14.1;Level: LLT;Classification code 10041597;Term: Spinal stenosis of lumbar region;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Forteo Product Name: Forsteo Product Code: 0002-8971 INN or Proposed INN: teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) Other descriptive name: rhPTH (1-34) | Middelfart Rygsektor | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Denmark | ||
40 | NCT02271191 (ClinicalTrials.gov) | May 2012 | 15/10/2014 | Effect of Nicardipine on Renal Function in Deliberate Hypotension | Effect of Nicardipine on Renal Function in Deliberate Hypotension | Spinal Stenosis | Drug: Nicardipine | Yonsei University | NULL | Completed | 20 Years | N/A | Both | 64 | Phase 4 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
41 | EUCTR2012-000747-26-FI (EUCTR) | 27/04/2012 | 02/04/2012 | Ketamine to reduce postoperative pain in back surgery | Administration of S-Ketamine during spinal surgery to reduce postoperative pain | adult patients undergoing spinal surgery MedDRA version: 14.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Helsinki Universiy Central Hospital | NULL | Not Recruiting | Female: yes Male: yes | 192 | Phase 4 | Finland | |||
42 | NCT01522846 (ClinicalTrials.gov) | January 2012 | 9/1/2012 | Heparin Solution and INTEM/HEPTEM Analysis | Influence by Heparinized Flush Solution of the Radial Artery Catheter: INTEM and HEPTEM Analysis. | Brain Tumor;Spinal Stenosis;Cerebral Artery Anuerysm | Drug: Heparin | Seoul National University Bundang Hospital | NULL | Completed | 20 Years | N/A | Both | 25 | N/A | Korea, Republic of |
43 | JPRN-UMIN000006588 | 2011/11/01 | 01/11/2011 | Effect of antiplatelet agent on muscle cramps after surgery of lumbar spinal stenosis in patients with lumbar spinal canal stenosis and peripheral artery disease | Lumbar spinal canal stenosis | Continuous administration of cilostazol | Juntendo UniversityDepartment of Orthopaedic Surgery | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 30 | Not applicable | Japan | |
44 | NCT01456377 (ClinicalTrials.gov) | July 2011 | 12/10/2011 | The Effectiveness of Oral Corticosteroids in the Treatment of Lumbar Stenosis | A Prospective Controlled Study Randomized Double Blind Study, Evaluate the Effectiveness of Oral Corticosteroids in the Treatment of Stenosis of Lumbar Canal In Symptomatic Patients | Spinal Stenosis of Lumbar Region | Drug: predinose oral;Drug: placebo group | Federal University of São Paulo | NULL | Recruiting | 50 Years | 75 Years | Both | 60 | N/A | Brazil |
45 | NCT01238536 (ClinicalTrials.gov) | April 2011 | 8/11/2010 | Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial) | Multicenter Randomized Controlled Trial of Epidural Steroid Injections for Spinal Stenosis in Persons 50 and Older | Spinal Stenosis;Low Back Pain | Procedure: Epidural steroid with local anesthetic injection;Procedure: Epidural local anesthetic injection;Drug: Epidural steroid injection;Drug: Epidural local anesthetic injection | University of Washington | Kaiser Permanente;University of California, San Francisco;Henry Ford Hospital;Harvard Pilgrim Health Care;Harvard Vanguard Medical Associates;University of Colorado, Denver;Mayo Clinic;Stanford University;Massachusetts General Hospital;Virginia Spine Research Institute;Oregon Health and Science University;Dallas VA Medical Center | Completed | 50 Years | N/A | All | 400 | Phase 4 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
46 | NCT01315145 (ClinicalTrials.gov) | March 2011 | 11/3/2011 | MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study | MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study | Lumbar Spinal Stenosis | Procedure: Percutaneous Lumbar Decompression;Drug: Epidural Steroid Injection | Vertos Medical, Inc. | NULL | Completed | 50 Years | N/A | All | 138 | N/A | United States |
47 | JPRN-UMIN000004825 | 2011/01/01 | 06/01/2011 | A randomized comparative study of Celecoxib and Limaprost alfadex on the patients with lumber spinal stenosis for the effectiveness for symptoms and QOL | Lumbar spinal stenosis | 15ug/day Limaprost arfadex for 8 weeks 200mg/day Celecoxib for 8 weeks | University of Tsukuba, Course of life-style related disorders donated by JA Ibaraki Public Welfare Federation | Mito Kyodo Hospital | Complete: follow-up complete | 40years-old | 85years-old | Male and Female | 134 | Phase 3 | Japan | |
48 | NCT01275547 (ClinicalTrials.gov) | January 2011 | 11/1/2011 | The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam | The Analgesic Effect of Combined Treatment With Intranasal S-Ketamine and Intranasal Midazolam Compared With Morphine Patient Controlled Analgesia in Spinal Surgery Patients | Analgesia, Patient-controlled;Spinal Stenosis | Drug: s-ketamine & midazolam;Drug: Morphine PCA | University Hospital, Basel, Switzerland | NULL | Completed | 18 Years | N/A | Both | 22 | Phase 2;Phase 3 | Switzerland |
49 | JPRN-UMIN000005382 | 2010/12/01 | 05/04/2011 | Intraoperative perineural infiltration of ropivacaine for acute postlaminectomy pain | lumbar spinal stenosis | General anesthesia and NSAIDs. As a contorol,saline 10ml infiltrate per one interspinal segment. Generalanesthesia and NSAIDs. 0.2%ropivacaine 10ml infiltrate per one interspinal segment. General anesthesia and NSAIDs. From catheter in injury part,administration of 0.2%ropivacaine 6ml/h. Duration of administration:2 days after the operation. | Higashi Ohmiya general hospital | NULL | Complete: follow-up complete | 20years-old | 75years-old | Male and Female | 60 | Not selected | Japan | |
50 | JPRN-UMIN000005959 | 2010/11/01 | 12/07/2011 | Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication | Patients with combined lumbar spinal stenosis and arteriosclerosis obliterans | Prostaglandin for injection (alprostadil) group: 60 mcg of prostaglandin for injection is intravenously administered once a week or more. This therapy is repeated 10 times or more. Ripple injection (alprostadil Injection) group: 10 mcg of ripple injection is administered intravenously once a week or more. This treatment is repeated 10 times or more. Conventional treatment group | Tokai University HospitalDepartment of Orthopaedic Surgery | NULL | Complete: follow-up continuing | 20years-old | Not applicable | Male and Female | 300 | Not selected | Japan | |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
51 | NCT03532945 (ClinicalTrials.gov) | October 28, 2010 | 2/5/2018 | A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion | A Long-term Follow-up Study to Evaluate the Efficacy and Safety for the Patients With Bioactive Glass-ceramic Intervertebral Spacer (Novomax) in Posterior Lumbar Interbody Fusion: Comparison With a Titanium Cage | Degenerative Lumbar Spinal Stenosis | Device: Bioactive Glass-Ceramic Spacer;Device: Titanium cage | BioAlpha Inc. | NULL | Completed | 30 Years | 80 Years | All | 62 | N/A | NULL |
52 | NCT01097486 (ClinicalTrials.gov) | June 2010 | 30/3/2010 | Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy | Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation | Cervical Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Biological: NeoFuse;Procedure: Allograft | Mesoblast, Ltd. | NULL | Completed | 18 Years | 70 Years | All | 24 | Phase 2 | United States |
53 | NCT01106417 (ClinicalTrials.gov) | June 2010 | 16/4/2010 | Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion | Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation | Cervical Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Biological: NeoFuse;Device: MasterGraft Granules | Mesoblast, Ltd. | NULL | Completed | 18 Years | 70 Years | All | 12 | Phase 1;Phase 2 | Australia |
54 | NCT01127100 (ClinicalTrials.gov) | May 2010 | 19/5/2010 | Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain | Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial | Neuropathic Pain;Spinal Stenosis | Drug: transdermal fentanyl matrix, gabapentin | Seoul National University Hospital | Seoul National University Bundang Hospital;Asan Medical Center;Inje University;Chonnam National University Hospital;Chung-Ang University Hosptial, Chung-Ang University College of Medicine;Dankook University | Completed | 20 Years | 80 Years | Both | 108 | Phase 4 | Korea, Republic of |
55 | NCT01052324 (ClinicalTrials.gov) | March 2010 | 11/1/2010 | The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation | The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation | Cervical Disc Herniation;Cervical Spinal Stenosis;Cervical Spine Damage | Drug: Remifentanil | Yonsei University | NULL | Completed | 20 Years | 65 Years | Both | 19 | Phase 4 | Korea, Republic of |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
56 | NCT00996073 (ClinicalTrials.gov) | September 2009 | 9/10/2009 | Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion | A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Lumbar Interbody Fusion With Instrumentation | Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Biological: Lumbar Interbody Fusion with Autograft;Biological: Lumbar Interbody Fusion with NeoFuse | Mesoblast, Ltd. | NULL | Completed | 18 Years | 70 Years | All | 24 | Phase 2 | United States |
57 | NCT00995371 (ClinicalTrials.gov) | August 2009 | 14/10/2009 | Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis | Comparative Study of Epidural Steroid Injection Versus Mild® (Minimally Invasive Lumbar Decompression) Procedure in Patients Diagnosed With Symptomatic Moderate to Severe Lumbar Central Canal Stenosis | Lumbar Spinal Stenosis | Device: MILD® (Minimally Invasive Lumbar Decompression);Drug: Epidural Steroid Injection | Coastal Orthopedics & Sports Medicine | Vertos Medical, Inc. | Completed | 18 Years | N/A | All | 38 | Phase 4 | United States |
58 | NCT00808665 (ClinicalTrials.gov) | June 2009 | 15/12/2008 | Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion | Does Continuous Perioperative Dexmedetomidine Infusion Reduce Time to Discharge in Patients Undergoing Major Lumbar Fusion? A Double-Blind, Placebo-Controlled Study | Spinal Fusion Acquired;Spinal Stenosis;Lesions of Lumbosacral Intervertebral Disc;Spinal Diseases | Drug: Dexmedetomidine;Drug: 0.9% Saline | Vanderbilt University Medical Center | NULL | Completed | 18 Years | 85 Years | All | 68 | Phase 4 | United States |
59 | NCT00908375 (ClinicalTrials.gov) | May 2009 | 21/5/2009 | Efficacy of Pregabalin in Patients With Radicular Pain | Efficacy of Pregabalin in Patients With Radicular Pain | Neuropathy; Radicular, Lumbar, Lumbosacral;Failed Back Surgery Syndrome;Spinal Stenosis;Herniated Disc | Drug: Pregabalin;Drug: Sugar Pill | Northwestern University | NULL | Completed | 18 Years | 64 Years | All | 39 | Phase 4 | United States |
60 | NCT00810212 (ClinicalTrials.gov) | November 2008 | 17/12/2008 | Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion | A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With Mastergraft Granules in Subjects Undergoing Posterolateral Lumbar Fusion With Instrumentation | Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Procedure: PLF with autograft;Biological: PLF with NeoFuse | Mesoblast, Ltd. | NULL | Withdrawn | 18 Years | 70 Years | All | 0 | Phase 1;Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
61 | NCT00638443 (ClinicalTrials.gov) | March 2008 | 12/3/2008 | Lumbar Stenosis Outcomes Research (LUSTOR) | Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Cross-over Trial of Pregabalin vs. Diphenhydramine in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain | Lumbar Spinal Stenosis | Drug: Pregabalin;Drug: Diphenhydramine | University of Rochester | Pfizer | Completed | 50 Years | N/A | All | 29 | Phase 4 | United States |
62 | NCT00652093 (ClinicalTrials.gov) | March 2008 | 11/3/2008 | Lumbar Stenosis Outcomes Research II | Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial | Lumbar Spinal Stenosis | Drug: opana then darvocet then placebo;Drug: opana then placebo then darvocet;Drug: placebo then opana then darvocet;Drug: Placebo then darvocet then opana;Drug: Darvocet then opana then placebo;Drug: Darvocet then placebo then opana | University of Rochester | Endo Pharmaceuticals | Terminated | 50 Years | N/A | All | 24 | Phase 4 | United States |
63 | NCT00549913 (ClinicalTrials.gov) | October 2007 | 24/10/2007 | Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF) | A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation. | Degenerative Disc Disease;Spondylolisthesis;Spinal Stenosis | Biological: NeoFuse;Procedure: posterolateral spinal fusion with instrumentation | Mesoblast, Ltd. | NULL | Completed | 18 Years | N/A | All | 6 | Phase 1;Phase 2 | United States |
64 | NCT00370799 (ClinicalTrials.gov) | January 2007 | 30/8/2006 | Effectiveness of Caudal Epidural Injections in Treatment of Chronic Low Back and Lower Extremity Pain | A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Caudal Epidural Injections in Lumbar Disc Herniations, Spinal Stenosis, Discogenic Pain, and Post-Lumbar Laminectomy Syndrome | Low Back Pain | Drug: Caudal epidural injection;Drug: Caudal Epidural Injection with generic Celestone;Drug: Caudal Epidural Injection with Celestone;Drug: Caudal Epidural Injection with DepoMedrol | Pain Management Center of Paducah | NULL | Completed | 18 Years | N/A | Both | 240 | Phase 0 | United States |
65 | NCT00320619 (ClinicalTrials.gov) | September 2000 | 28/4/2006 | Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery | Aminocaproic Acid and Bleeding in Spinal Surgery | Scoliosis;Kyphosis;Lordosis;Spondylitis;Spinal Stenosis | Drug: Epsilon-Aminocaproic Acid (EACA);Drug: Placebo | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 18 Years | N/A | Both | 182 | N/A | United States |